- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02558998
Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care
February 4, 2020 updated by: Abramson Cancer Center of the University of Pennsylvania
The objective of this study is to 1) evaluate the impact of a novel individualized care planning/ educational technology (the On Q Care Planning System or CPS) on oncology patient and provider knowledge, attitudes and beliefs about Non-Small Cell Lung Carcinoma (NSCLC) clinical trials, as well as 2) to evaluate the impact of the On Q CPS on patient referral to and enrollment in NSCLC clinical trials.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Abramson Cancer Center of The University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- All participants must be 18 years of age or older.
- Patient participants must have Stage III, IV and/or recurrent NSCLC.
- Patient participants must be at a point of treatment initiation/change or evaluation for treatment initiation/change
- Patients must have working email address and internet access
Exclusion Criteria:
- Any participant who cannot understand written or spoken English.
- Any participant who is not competent to provide informed consent for study participation per the investigator.
- Any participant who cannot be present for the related study visits and/or complete the post-test assessment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patient who completed surveys
Time Frame: 8 months
|
8 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Joshua Bauml, MD, Abramson Cancer Center of The University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2015
Primary Completion (Actual)
March 1, 2019
Study Completion (Actual)
March 1, 2019
Study Registration Dates
First Submitted
June 19, 2015
First Submitted That Met QC Criteria
September 23, 2015
First Posted (Estimate)
September 24, 2015
Study Record Updates
Last Update Posted (Actual)
February 6, 2020
Last Update Submitted That Met QC Criteria
February 4, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPCC 34514
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Small Cell Lung Carcinoma (NSCLC)
-
Revolution Medicines, Inc.RecruitingNon-Small Cell Lung Cancer | NSCLC | NSCLC (Non-small Cell Lung Cancer) | NSCLC (Advanced Non-small Cell Lung Cancer) | NSCLC (Non-small Cell Lung Carcinoma)Japan, Netherlands, Hong Kong, United States, United Kingdom, Belgium, Australia, Spain, Germany, Switzerland, Italy, Taiwan, France, Singapore, Poland, South Korea, Puerto Rico, Ireland, New Zealand
-
University of MalayaRecruitingNon Small Cell Lung Carcinoma NSCLCHong Kong, Malaysia
-
PfizerRecruitingCarcinoma | Lung Neoplasms | Non-Small Cell Lung Cancer | Lung Disease | Non-Small-Cell Lung | Carcinoma, Non-Small-Cell Lung (NSCLC) | Non-small Cell Lung Cancer, Squamous | Non-small Cell Lung Cancer, Non-squamous | Lung Cancer (NSCLC)United States, Puerto Rico
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
Technische Universität DresdenDeutsche Krebshilfe e.V., Bonn (Germany); Universitätsklinikum KölnNot yet recruitingNSCLC Stage IIIB~IV | NSCLC (Advanced Non-small Cell Lung Cancer) | NSCLC Non-small Cell Lung CancerGermany
-
Massachusetts General HospitalSummit TherapeuticsNot yet recruitingLung Cancer Non Small Cell | Genomic Alterations | Lung Cancer (Non-Small Cell) | Lung Cancer (NSCLC) | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer - Non Small CellUnited States
-
Tianjin Medical University Cancer Institute and...RecruitingNSCLC (Non-small Cell Lung Cancer) | NSCLC (Advanced Non-small Cell Lung Cancer)China
-
Mythic TherapeuticsTerminatedNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Spain, Taiwan, Australia, United Kingdom, France, South Korea
-
Jun Zhang, MD, PhDGenentech, Inc.; ExelixisNot yet recruitingLung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
GFPC InvestigationRecruitingNon-Small Cell Lung Cancer | NSCLC | Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Carcinoma | EGFR | Non Small Cell Lung Cancer NSCLC | EGFR Exon 20 Insertion Mutation | EGFR Exon 19 Deletion Mutation | EGFR Exon 21 MutationFrance
Clinical Trials on Survey
-
Johns Hopkins Bloomberg School of Public HealthPontificia Universidad JaverianaCompletedNoncommunicable Diseases | Surveys and QuestionnairesColombia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSarcoma | Breast Carcinoma | Head and Neck CarcinomaUnited States
-
Weill Medical College of Cornell UniversityBoston Children's Hospital; Brigham and Women's Hospital; The Commonwealth FundCompletedPediatric ALLUnited States
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; Université de Cergy PontoiseCompleted
-
Sarasota Memorial Health Care SystemEnrolling by invitation
-
Ohio State UniversityWithdrawnMedicare Part DUnited States
-
Johns Hopkins Bloomberg School of Public HealthIfakara Health InstituteCompletedNoncommunicable Diseases | Surveys and QuestionnairesTanzania
-
Memorial Sloan Kettering Cancer CenterCompletedInpatients With Limited English ProficiencyUnited States
-
Lawson Health Research InstituteCompletedEvaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation ParticipationMyocardial Infarction | Unstable Angina | Coronary Angioplasty | Coronary Artery Bypass SurgeryCanada